Paxman's Q3 revenue rises on strong US sales, Reuters reports
Swedish medtech maker Paxman posted higher quarterly revenue and net income, driven by strong US sales. Figures are based on Reuters reporting.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Swedish medical technology company Paxman reported higher group revenue for the third quarter compared with a year earlier. The main driver was US sales, which rose 27%, with the insurance-based billing model showing particular strength.
Net income and earnings per share for the quarter also improved year on year, with EPS at 0.34 Swedish kronor. The company brought its cryocompression neuropathy system to commercial launch, expanding its portfolio beyond scalp cooling products.
Paxman expects an FDA De Novo review of the system to extend its timeline for US market entry. Initial UK orders and a commercial launch are planned for the fourth quarter of 2026.
why it matters
For investors, the report shows a small medtech maker growing through the US market and insurance reimbursement. The FDA timeline and the company's view that California insurance law will support its billing model will shape the pace of US growth.
market impact
Paxman shares: strong US sales growth supports the company's business outlook
tags
instruments
sources
- Swedish medtech firm Paxman's Q3 revenue rises on strong US sales — Reuters, 20 November 2026 at 06:09 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗